Impact of the COVID-19 pandemic on the care of patients with malignant diseases - A retrospective, multicenter, non-interventional study of the East German Study Group for Hematology and Oncology (OSHO)
- Conditions
- Malignant diseases
- Registration Number
- DRKS00027370
- Lead Sponsor
- Krukenberg Krebszentrum Halle
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 4070
Inclusion Criteria
Age > 18 years
- newly diagnosed malignant tumors according to ICD-10 in 2018, 2019, and 2020
Exclusion Criteria
- Patients actively contradicting the consent for data collection
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of newly diagnosed malignant tumors according to ICD-10 per month in 2020 compared to 2018 and 2019.
- Secondary Outcome Measures
Name Time Method - Number of newly diagnosed malignancies, differentiated by individual tumor entity (monthly comparison between the years 2020, 2019 and 2018)<br>- Interval between diagnosis and initiation of therapy, differentiated by individual tumor entity (monthly comparison between 2020, 2019, and 2018)<br>- Stage of disease in solid neoplasms (TNM) at the time of diagnosis differentiated by individual tumor entities (monthly comparison between the years 2020, 2019, and 2018)<br>- Outcome of disease (survival, event-free survival, recurrence incidence, and mortality incidence) at 1 and 2 years (comparison between new diagnoses in 2020, 2019, and 2018)<br>- Influence of patient-related factors (age, sex, geographic residence based on zip code) on primary and above secondary endpoints.<br>- Influence of disease-related factors (diagnosis, time of diagnosis, interval between diagnosis and initiation of therapy, TNM) on outcome.